Studies on chloramphenicol. II. Possible determinants and progress of haemopoietic toxicity during chloramphenicol therapy.
D000293:Adolescent; D000367:Age Factors; D000380:Agranulocytosis / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D004906:Erythrocyte Count; D006402:Hematologic Diseases / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006410:Hematopoiesis; D006801:Humans; D007223:Infant; D007501:Iron / Q000097:blood*; D009504:Neutrophils; D010649:Phenylalanine / Q000627:therapeutic use; D011379:Prognosis; D012156:Reticulocytes; D012256:Riboflavin / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014803:Vitamin B Complex / Q000627:therapeutic use
D014803:Vitamin B Complex; D010649:Phenylalanine; D002701:Chloramphenicol; D007501:Iron; D012256:Riboflavin